A simultaneous CRC and liver operation was performed in 329 (33%) patients; 675 (67%) underwent a staged approach ("classic" staged approach, n ¼ 647; liver-first strategy, n ¼ 28). Patients managed with the liver-first approach had more hepatic lesions and were more likely to have bilateral disease than those in the other 2 groups (p < 0.05). The use of staged operative strategies increased over the time of the study from 58% to 75% (p < 0.001). Liverdirected therapy included hepatectomy (90%) or combined resection þ ablation (10%). A major resection (>3 segments) was more common with a staged approach (39% vs 24%; p < 0.001). Overall, 509 patients (50%) received chemotherapy in either the preoperative (22%) or adjuvant (28%) settings, with 11% of patients having both. There were 197 patients (20%) who had a complication in the postoperative period, with no difference in morbidity between staged and simultaneous groups or major vs minor hepatectomies (p > 0.05). Ninety-day postoperative mortality was 3.0%, with no difference between simultaneous and staged approaches (p ¼ 0.94). The overall median and 5-year survivals were 50.9 months and 44%, respectively; long-term survival was the same regardless of the operative approach (p > 0.05). CONCLUSIONS: Simultaneous and staged resections for sCRLM can be performed with comparable morbidity, mortality, and long-term oncologic outcomes. (J Am Coll Surg 2013;216: 707e718. Ó 2013 by the American College of Surgeons)
Colorectal cancer (CRC) accounts for more than 51,000 deaths each year in the United States, making it the second most common cause of cancer-related deaths. 1 Approximately one-half of patients with CRC will develop liver metastasis during the course of their disease, with 15% to 42% presenting with synchronous primary CRC and colorectal liver metastasis (CRLM). [2] [3] [4] Surgical therapy of CRLM remains the only therapeutic option with potential for cure. 5, 6 In modern series, the overall 5-year survival reported after hepatic resection with curative intent ranges from 35% to 58%. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Traditionally, a staged approach (colorectal first) has been used in the management of patients with synchronous CRLM (sCRLM). This involves the initial extirpation of the primary CRC, often followed by systemic chemotherapy, followed later by a liver-directed operation to address the hepatic disease. The last 2 decades have brought an increased understanding of the biology of CRLM, resulting in more effective targeted therapies in addition to decreased mortality after liver-directed operations. 4, 11, 19 These developments have led surgeons managing patients with sCRLM to consider other operative sequences such as a liver-first (reverse strategy) staged approach, in which the hepatic disease is addressed, followed by extirpation of the primary CRC at later date. [20] [21] [22] In patients with clearly resectable CRLM, several investigators have advocated for a simultaneous resection of both the primary CRC and CRLM in the same operative setting. 23, 24 There have been limited data published comparing all 3 operative strategies for patients with sCRLM. In particular, previous studies have not focused especially on the degree of morbidity and mortality. In this study, we sought to determine the safety and efficacy of the 3 operative strategies for patients with sCRLM in a large, multi-institutional, international analysis. Specifically, we examined the short-and long-term outcomes of patients who were managed with curative intent liverdirected operations in patients with sCRLM. In addition, we identified factors predictive of complications and clinicopathologic characteristics associated with long-term survival after curative intent, liver-directed operations for patients with sCRLM in a large international multicenter cohort.
METHODS
Between October 1982 and June 2011, 1,004 patients treated with curative intent surgery for synchronous colorectal and CRLM were identified from 4 major hepatobiliary centers in the United States (Johns Hopkins School of Medicine, Baltimore, MD) and Europe (Hôpitaux Universitaires de Genève, Geneva, Switzerland; Unit of Hepato-Biliary-Pancreatic Surgery, Lisbon, Portugal; Ospedale San Raffaele, Milan, Italy); the study was approved by the institutional review boards of the respective institutions.
Patients were divided into 3 groups: those undergoing a staged procedure in which the primary CRC was extirpated first, followed at a later date by liver-directed therapy ("colorectal first" or "classic approach"); patients managed in a staged fashion in which the CRLM was addressed first followed at a later date by the CRC primary ("liver first" or "reverse strategy"); and those patients who were managed with a simultaneous resection of both the CRC primary and CRLM in the same operative setting ("simultaneous"). Additionally, patients were categorized as having either a "simultaneous" or a "staged" operation depending on the timing of the operations. Patients who underwent previous hepatic resections or ablations of the CRLM were excluded from this study. Only patients who had surgery with curative intent either with resection or combined resection plus ablation were included; patients undergoing ablative procedures only were excluded. If the patient had extrahepatic colorectal metastasis, the extrahepatic disease had to be surgically addressed with curative intent either at the time of the hepatic operation or at another date for the patient to be included in the study cohort.
Data collection
Standard demographic and clinicopathologic data for each patient as well as data on tumor characteristics of the primary CRC and of the CRLM were collected. Data were collected on the primary CRC location (rectal vs colon) and the date of CRC operation, if a staged procedure (ie, colorectal first or liver first). For the CRLM, data were collected on the number, size in centimeters, the number of CRLM treated, and the distribution of the hepatic metastasis (unilateral or bilateral) at the time of the liver-directed operation. Resection at the time of surgery was classified as less than a hemihepatectomy (eg, segmentectomy or subsegmentectomy), hemihepatectomy, or extended hepatectomy (!5 liver segments) per the Brisbane standardized nomenclature. 25 Additionally, the extent of resection was further classified as a "major" (!3 segments) or "minor" (<3 segments) hepatectomy. The use of concomitant ablation was also noted. The use and timing of perioperative chemotherapy was also noted; the specific regimen was not defined because this differed greatly across the international patient spectrum. Hepatic resection margins were classified as R0 (microscopically negative), R1 (microscopically positive), and R2 (grossly positive). These data referred to the margin status of resected liver metastasis; if the patient underwent a combined resection plus ablation, the margin status referred to the resected specimen.
Perioperative morbidity and mortality data were collected and graded according to the system proposed by Clavien and colleagues, which included the therapeutic consequences of complications within 90 days of the liver-directed operation. 26 Severe complications were Abbreviations and Acronyms CRC ¼ colorectal cancer CRLM ¼ colorectal liver metastasis HR ¼ hazard ratio sCRLM ¼ synchronous colorectal liver metastasis classified as ! Grade IIIa and included those complications treated with surgical, endoscopic, or radiologic interventions or resulting in death (Grade V). Dates of last follow-up, vital status, and recurrence of CRLM were collected on all patients. Hepatic recurrences of the CRLM were calculated only for patients who were alive at 90 days. 27 Statistical analyses Summary statistics were obtained using established methods and presented as percentages or median values with standard deviation. Fisher's exact test was used for cells with n < 5 and the Bonferroni adjustment was used for comparisons of multiple proportions. Factors associated with complications were examined using logistic regression modeling. To identify variables for inclusion in the multivariate model, variables were selected using the Hosmer and Lemeshow criteria of p < 0.25 in combination with important clinical variables and confounders. 28, 29 The final multivariate model's performance and discriminative ability were examined using the Hosmer and Lemeshow goodness-of-fit test and receiver operating characteristic curves (ROC). Survival was calculated from the date of the liver-directed operation to the date of last contact or death and was estimated using the nonparametric product limit method described by Kaplan and Meier. 30 Differences in survival were examined using the log-rank (Mantel-Cox) test. Factors associated with survival were examined using univariate and multivariate Cox regression analyses. The multivariate model was built using purposeful direct entry based on the Wald statistic, with all variables with p < 0.25 included in the multivariate model. The hazard ratio (HR) and the 95% confidence intervals (CI) were estimated and a p < 0.05 was considered significant. All statistical analyses were 2-sided and were performed using Statistical Packages for the Social Sciences (SPSS, IBM, Version 20.0).
RESULTS

Patient, tumor, and operative details
Among the 4 institutions, there were 1,004 patients with CRC and sCRLM who underwent operative management of both the primary and metastatic liver disease. The majority of patients were men (n ¼ 598; 59.6%) with a median age of 60.0 years (SD 22.5 years). Most patients presented with a colon primary (n ¼ 726; 72.3%). Among patients with sCRLM, 38.4% (n ¼ 380) had bilateral disease, the median number of CRLMs was 2.0 (SD 2.6), and median tumor size was 3.5 cm (SD 3.0 cm). Overall, 509 patients (50%) received chemotherapy; 22.2% of patients (n ¼ 222) received preoperative chemotherapy only, 28.5% (n ¼ 287) adjuvant therapy only, and 10.7% (n ¼ 108) both pre-and postoperative chemotherapy.
Management of patients with staged operative procedures (ie, classic colorectal first and liver first) increased from 57.5% to 74.8% over the course of study period (p < 0.001; Fig. 1 ). This paralleled an increase in the burden of CRLM disease treated over time (1982 to 1996: median tumor number, 1.0 vs 1997 to 2011: median tumor number, 2.0; p < 0.001). Of the 675 patients (67.2%) whose disease was managed in a staged fashion, the vast majority had the CRC primary addressed first (colorectal first: n ¼ 647; 64.4% vs liver first: n ¼ 28; 2.8%). Only in the last 5 years was there an increased use of the reverse strategy approach (Fig. 1) . A comparison of the preoperative characteristics of patients who underwent classic, liver first, or the simultaneous approach is detailed in Table 1 . Although patients in the classic and simultaneous groups had a comparable number and size of CRLM, patients managed with a liver-first approach were more likely to have bilateral disease than those in the other 2 groups (p ¼ 0.028). Patients managed with the liver-first approach also had more hepatic lesions treated at the time of the liver-directed operation (median 4.0, SD 3.4) compared with the other groups (p ¼ 0.006). In addition, Figure 1 . Surgical management of 1,004 patients with synchronous colorectal liver metastasis over time. The use of staged operative strategies (colorectal primary/liver, and liver/colorectal primary) increased over time as compared with simultaneous resections of both the primary and liver disease (p < 0.001). Operative strategy: red bar, simultaneous; blue bar, liver first (liver/colorectal cancer); green bar, colorectal cancer first (colorectal cancer/liver).
patients undergoing a liver-first approach were more likely to have a rectal primary tumor (n ¼ 15; 53.6%) compared with patients undergoing either a colorectal-first or a simultaneous approach (p ¼ 0.007). Overall, 117 patients (11.7%) had extrahepatic metastatic disease, with no difference between the 3 groups (p > 0.05). The majority of patients managed with a liver-first approach (n ¼ 21; 75.0%) received preoperative treatment as compared with approximately one-third in the colorectal-first and simultaneous groups (p < 0.001). Conversely, patients managed with either colorectal-first or simultaneous resections were more likely to receive adjuvant chemotherapy than liver-first patients (p ¼ 0.012).
The vast majority of patients in all 3 groups were managed with hepatic resection alone (overall, n ¼ 899; 89.5%; p > 0.05); only a minority of patients were treated with combined resection plus ablation (n ¼ 105; 10.5%). There was no difference in the use of resection plus ablation among patients treated with either a staged or simultaneous approach (p ¼ 0.454). A combined modality 
Perioperative outcomes
Among the 947 patients in whom complete complication data were available, 197 patients (19.6%) had a complication in the postoperative period; the overall incidence of complications was similar among the 3 groups (p > 0.05; Fig. 2 , Table 2 ). Of note, the overall proportion of patients who experienced a severe complication (Clavien Grades IIIa, IIIb, IVa, IVb, or V) did not differ between patients treated with the staged or simultaneous approach (p > 0.05). Patients who underwent a minor hepatectomy using a simultaneous approach had overall and severe complication incidences of 19.3% and 12.1%, respectively (Table 3 ). In comparison, simultaneous major hepatectomy was associated with similar overall and severe complication incidences (25.0% and 15.8%, respectively; both p > 0.05). Among patients who underwent a staged approach, the overall (16.5% and 23.7%) and severe (10.7% and 13.8%) complications were similar among patients undergoing a minor or major hepatectomy, respectively. Of note, for patients undergoing a major hepatectomy, there was no difference in overall complications, minor complications, or severe complications between patients managed in a staged vs simultaneous fashion (all p > 0.05). On univariate logistic regression analysis, major hepatectomy was associated with an increased odds of having a complication (p ¼ 0.049) and this factor remained an independent predictor of morbidity on multivariate analyses (odds ratio 1.42; [95% CI, 1.01 to 2.00]; p ¼ 0.044; Table 4 ). There were 30 patient deaths, for a 90-day mortality of 3.0%. Mortality was comparable when comparing patients treated with a simultaneous (2.7%) vs staged (3.1%) approach (p ¼ 0.743). Patients who died within 90 days of the liver-directed operation were similar with regard to patient age, location of the CRC primary, tumor size, number, and distribution of the hepatic disease compared with patients who survived beyond 90 days (all p > 0.05). In addition, when comparing simultaneous vs staged approaches, there was no difference in the 90-day postoperative mortality of patients undergoing a partial hepatectomy (1.7% vs 3.6%) or hemihepatectomy (5.7% vs 3.3%; both p > 0.05). The mortality associated with an extended hepatectomy performed simultaneously was 8.0% vs 2.8% when done as part of a staged approach (p > 0.05).
Recurrence and predictors of survival
Among the 974 patients who did not die within 90 days, at a median follow-up of 34 months, 556 (57.0%) patients suffered recurrence. Recurrence was similar when comparing the simultaneous (59.6%) vs staged (57.2%) approaches (p ¼ 0.171). Although a simultaneous or staged approach was not associated with the risk of recurrence, on univariate logistic regression, history of a rectal primary tumor and more than 2 CRLM were associated with an increased odds of recurrence (both p < 0.05); on multivariate analysis, a rectal primary tumor site remained significant (odds ratio 2.14; 95% CI 1.47 to 2.99; p < 0.001).
The median overall survival after the liver-directed operation was 50.9 months (95% CI 44.8 to 56.9 months). The 1-, 3-, and 5-year overall survivals were 89%, 60%, and 44%, respectively (Fig. 3a ). Patients managed with simultaneous or staged approaches had a similar 5-year survivals (42% vs 44%; p ¼ 0.688); in fact, there were no differences in overall survival when comparing the colorectal-first, liver-first, or simultaneous approaches (p ¼ 0.526; Fig. 3b ). On univariate analyses, factors associated with survival included male sex, rectal primary, more than 2 CRLM, and combined resection plus ablation (all p < 0.05). Specifically, patients who had more than 2 CRLM had a worse survival (43.2 months) compared with patients who underwent hepatectomy for 2 or fewer lesions (59.8 months; p ¼ 0.019). In addition, the median survival for patients undergoing a combined resection plus ablation was 35 Table 5) .
DISCUSSION
Colorectal cancer remains the most common indication for hepatic resection in patients with metastatic disease. 1, 31 Up to 25% to 30% of patients with CRC will present with sCRLM. The optimal timing for surgical resection for patients with sCRLM has been a topic of much debate, and data on the topic continue to evolve. Given that morbidity and mortality associated with hepatectomy have decreased substantially over the past 20 years, the classic paradigm of a staged operation for sCRLM has been questioned. Specifically, given the improved feasibility and safety of performing major hepatic resections, some investigators have suggested that the simultaneous For simultaneous resections this represents any complication related to primary or liver resection and for staged resections this represents complications after liver-directed operation.
z No reporting of perioperative mortality in the liver-first group because of inclusion of patients who underwent both a colorectal and hepatic operation.
x Recurrences calculated only for 974 patients who were alive at 90 days. CRLM, colorectal liver metastasis.
approach to sCRLM may be preferable. 21, 32, 33 Past data have been limited, with previous studies being from a single institution, 21, 32 having relatively few patients in each of the different operative strategy categories, 21, 32, 34, 35 or failing to include the liver-first reverse strategy in their analyses. 23 This study is important because it analyzed a large, multicenter, international cohort of patients who underwent surgical management of sCRLM. As such, the results of the study are more likely to be representative and generalizable than previous single-center studies. In addition, all 3 operative approaches (simultaneous, classic staged, and liver-first) were evaluated in the treatment of patients with sCRLM. We found that simultaneous and staged resections for sCRLM can be performed with comparable morbidity and mortality, as well as similar long-term oncologic outcomes. In this study, the overall morbidity and mortality were 19.6% and 3.0%, respectively. Perioperative outcomes did not differ among patients treated with a staged or simultaneous approach. In addition, morbidity and mortality were comparable among patients who underwent a minor or major hepatectomy, regardless of the operative strategy used. In a study of patients with sCRLM, Martin and colleagues 33 similarly reported no For simultaneous resections this represents any complication related to primary or liver resection and for staged resections this represents complications after liver-directed operation. Fisher's exact test used for cells with n < 5.
difference in morbidity or mortality comparing the staged vs simultaneous approaches. Broquet and associates 21 also did not note a difference in the postoperative morbidity between staged and simultaneous operations, although these data were not stratified by major compared with minor hepatectomy. Although Reddy and coworkers 23 noted no difference in perioperative outcomes with minor hepatectomy, the authors did report an increase in morbidity and mortality with the simultaneous approach and major hepatectomy. In the present study, we noted an increase in mortality among patients who underwent an extended hepatic resection during a simultaneous (8.0%) vs staged (2.8%) approach. This trend was not statistically significant, but the small number of patients who underwent an extended hepatic resection may have contributed to a type II statistical error. In the majority of cases, however, both minor and major hepatectomy appeared to be equally safe as part of either a staged or a simultaneous approach.
Regarding the long-term oncologic outcomes, the median and 5-year survivals after resection of both the primary CRC and CRLM in patients with sCRLM were 51 months and 44%, respectively. In addition, we found that 57% of patients experienced a recurrence, with a median follow-up of 34 months. Perhaps more interesting was our finding that the operative strategy for sCRLM had no impact on long-term outcomes (Fig. 3) . In a much smaller, single institution cohort, Broquet and colleagues 21 had similarly reported comparable overall survival among patients treated with the classic, simultaneous, or liver-first approach. Rather than operative strategy, tumor-specific factors were more associated with long-term oncologic success. For example, the need to use combined resection plus ablation for patients with more extensive disease was associated with a worse long-term survival, regardless of whether the timing of the operation was simultaneous or staged. These data serve to underscore the importance of biology and not technique in the prognosis of patients with sCRLM.
Historically the debate surrounding the management of patients with sCRLM has included only the classic staged vs simultaneous approach, but the liver-first/ reverse strategy staged approach recently has gained interest among surgeons. First reported by Mentha and colleagues 36 in 2006, the reverse strategy approach was proposed as a possible means to minimize the delay in treating CRLM in patients with sCRLM. In this study, the majority of patients treated with the liver-first approach had a rectal primary tumor. The reverse strategy may be particularly beneficial in this group because these patients often require chemotherapy, radiotherapy, and a complex pelvic operation. As such, the classic staged approach (ie, rectal tumor followed by liver at a later date) can result in a significant delay in the treatment of the CRLM. To avoid this delay in treating the liver disease, a liver-first strategy may be more applicable to patients with sCRLM and a rectal primary. 22 In this series, more than 50% of the liver-first operations were performed in the last 5 years of our study. Despite liver-first patients having a greater hepatic disease burden and undergoing major resection more often, the reverse strategy was safe and had long-term outcomes comparable to those of the other groups.
This study had several limitations. The data were retrospective in nature, and accurate collection of all complications may have been problematic and might have led to under-reporting of overall morbidity. We reported an overall morbidity of 19.6% after surgery for sCRLM, which was consistent with morbidity data reported from some large hepatobiliary centers, 35, 37, 38 but lower than others. 23, 32, 33 Given that our cohort included only patients who underwent both resection of the primary colorectal tumor and the liver metastasis, there may have been a reporting bias. Specifically, data on patients who were intended to undergo the staged approach but who never underwent the second operation would have been under-represented in our data set. Therefore, it is possible that an intention-to-treat analysis may have revealed an even higher incidence of morbidity or mortality in the staged group.
CONCLUSIONS
In conclusion, sCRLM patients managed with either a staged or simultaneous approach had similar perioperative and long-term outcomes. Both minor and major hepatectomy can be performed safely with low morbidity and mortality as part of either a simultaneous or a staged operative strategy. Although not statistically different, patients who underwent an extended hepatic resection did seem to have a higher perioperative mortality. As such, caution should still be exercised when considering an extended hepatectomy as part of a simultanteous approach to sCRLM. Oncologically, patients managed with a staged or simultaneous approach had similar recurrence and overall survival. These data indicated that longterm outcomes among patients with sCRLM are dictated by biology, not surgical strategy. 
